Ascites and spontaneous bacterial peritonitis: An Asian perspective

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 9, 2009, Pages 1494-1503

  Lee, Jung Min ^a   Han, Kwang Hyub ^a,b,c   Ahn, Sang Hoon ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Centre   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

Ascites; Asian perspective; Cirrhosis; Spontaneous bacterial peritonitis

Indexed keywords

ALBUMIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CHINESE DRUG; CLONIDINE; DIURETIC AGENT; DOCARPAMINE; FUROSEMIDE; MANNITOL; MIDODRINE; OFLOXACIN; PLACEBO; PROPRANOLOL; RECOMBINANT HUMAN SERUM ALBUMIN; SATAVAPTAN; SPIRONOLACTONE; TERLIPRESSIN;

ASCITES; ASIA; BACTERIAL PERITONITIS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE INCREASE; HEPATORENAL SYNDROME; HIGH RISK PATIENT; HUMAN; HYPONATREMIA; LIVER CIRRHOSIS; PARACENTESIS; PATHOGENESIS; PORTAL HYPERTENSION; PRIORITY JOURNAL; REVIEW; SODIUM RESTRICTION; SPLANCHNIC BLOOD FLOW; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; UNSPECIFIED SIDE EFFECT; WATER DEPRIVATION;

ASCITES; ASIA; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; LIVER CIRRHOSIS; PERITONITIS; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 69949186405     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06020.x     Document Type: Review

References (81)

1. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann. Intern. Med. 1992 117 : 215 220.
2. Moore KP, Wong F, Gines P et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003 38 : 258 266.
3. Planas R, Montoliu S, Ballesté B et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin. Gastroenterol. Hepatol. 2006 4 : 1385 1394.
4. Hui AY, Chan HL, Leung NW, Hung LC, Chan FK, Sung JJ. Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. J. Clin. Gastroenterol. 2002 34 : 569 572.
5. Kim SU, Han KH, Nam CM et al. Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. J. Gastroenterol. Hepatol. 2008 23 : 1722 1727.
6. Ginés P, Quintero E, Arroyo V et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987 7 : 122 128.
7. Huo TI, Lin HC, Lee FY et al. Occurrence of cirrhosis-related complications is a time-dependent prognostic predictor independent of baseline model for end-stage liver disease score. Liver Int. 2006 26 : 55 61.
8. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988 8 : 1151 1157.
9. Ginès P, Cárdenas A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N. Engl. J. Med. 2004 350 : 1646 1654.
10. Martin PY, Ginès P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N. Engl. J. Med. 1998 339 : 533 541.
11. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J. Hepatol. 2007 46 : 927 934.
12. Ginès P, Cárdenas A. The management of ascites and hyponatremia in cirrhosis. Semin. Liver Dis. 2008 28 : 43 58.
13. Sotoudehmanesh R, Shirazian N, Asgari AA, Malekzadeh R. Tuberculous peritonitis in an endemic area. Dig. Liver Dis. 2003 35 : 37 40.
14. Sen S, De BK, Biswas PK, Biswas J, Das D, Maity AK. Hemodynamic effect of spironolactone in liver cirrhosis and propranolol-resistant portal hypertension. Indian J. Gastroenterol. 2002 21 : 145 148.
15. Pamuk ON, Sonsuz A. The effect of mannitol infusion on the response to diuretic therapy in cirrhotic patients with ascites. J. Clin. Gastroenterol. 2002 35 : 403 405.
16. Singh V, Kumar R, Nain CK, Singh B, Sharma AK. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study. J. Gastroenterol. Hepatol. 2006 21 : 303 307.
17. Kasahara A, Kita K, Tomita E, Toyota J, Imai Y, Kumada H. Repeated administration of recombinant human serum albumin caused no serious allergic reactions in patients with liver cirrhosis: a multicenter clinical study. J. Gastroenterol. 2008 43 : 464 472.
18. Choi CH, Ahn SH, Kim DY et al. Long-term clinical outcome of large volume paracentesis with intravenous albumin in patients with spontaneous bacterial peritonitis: a randomized prospective study. J. Gastroenterol. Hepatol. 2005 20 : 1215 1222.
19. Amarapurkar DN, Punamiya S, Patel ND. An experience with covered transjugular intrahepatic portosystemic shunt for refractory ascites from western India. Ann. Hepatol. 2006 5 : 103 108.
20. Funasaki T, Tsutsumi M, Takase S et al. Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study. Am. J. Gastroenterol. 1999 94 : 2475 2481.
21. Tong GD, Zhou DQ, He JS et al. Clinical research on navel application of Shehuang Paste combined with Chinese herbal colon dialysis in treatment of refractory cirrhotic ascites complicated with azotemia. World J. Gastroenterol. 2006 12 : 7798 7804.
22. Stiehm AJ, Mendler MH, Runyon BA. Detection of diuretic-resistance or diuretic-sensitivity by the spot urine Na/K ratio in 729 specimens from cirrhotics with ascites: approximately 90% accuracy as compared to 24 hr urine Na excretion. Hepatology 2002 36 : 222A.
23. Arroyo V, Fernandez J, Ginès P. Pathogenesis and treatment of hepatorenal syndrome. Semin. Liver Dis. 2008 28 : 81 95.
24. Pérez-Ayuso RM, Arroyo V, Planas R et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology 1983 84 : 961 968.
25. Ginés P, Arroyo V, Quintero E et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987 93 : 234 241.
26. Ginès P, Titó L, Arroyo V et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988 94 : 1493 1502.
27. Ruiz-del-Arbol L, Monescillo A, Jimenéz W, Garcia-Plaza A, Arroyo V, Rodés J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997 113 : 579 586.
28. Moreau R, Valla DC, Durand-Zaleski I et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail. Liver Int. 2006 26 : 46 54.
29. Cárdenas A, Arroyo V. Management of ascites and hepatic hydrothorax. Best Pract. Res. Clin. Gastroenterol. 2007 21 : 55 75.
30. Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L. Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann. Intern. Med. 1995 122 : 816 822.
31. Russo MW, Sood A, Jacobson IM, Brown RS. Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality. Am. J. Gastroenterol. 2003 98 : 2521 2527.
32. Albillos A, Bañares R, González M, Catalina MV, Molinero LM. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J. Hepatol. 2005 43 : 990 996.
33. D'Amico G, Luca A, Morabito A, Miraglia R, D'Amico M. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 2005 129 : 1282 1293. (Pubitemid 41446867)
34. Salerno F, Cammà C, Enea M, Rössle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007 133 : 825 834.
35. Bureau C, Pagan JC, Layrargues GP et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int. 2007 27 : 742 747.
36. Won JY, Choi SY, Ko HK et al. Percutaneous peritoneovenous shunt for treatment of refractory ascites. J. Vasc. Interv. Radiol. 2008 19 : 1717 1722.
37. Kuiper JJ, de Man RA, van Buuren HR. Review article: management of ascites and associated complications in patients with cirrhosis. Aliment. Pharmacol. Ther. 2007 26 : 183 193.
38. Chan HL, Chim AM, Lau JT, Hui AY, Wong VW, Sung JJ. Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B. Am. J. Gastroenterol. 2006 101 : 1516 1523.
39. Wong VW, Chim AM, Wong GL, Sung JJ, Chan HL. Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B. Liver Transpl. 2007 13 : 1228 1235.
40. Huo TI, Lin HC, Wu JC et al. Limitation of the model for end-stage liver disease for outcome prediction in patients with cirrhosis-related complications. Clin. Transplant. 2006 20 : 188 194.
41. Lee YM, Fernandez M, Da Costa M et al. MELD may not be the better system for organ allocation in liver transplantation patients in Singapore. Singapore Med. J. 2006 47 : 592 594.
42. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 2008 371 : 1624 1632.
43. Ginès P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 2008 48 : 204 213.
44. Wong F, Ginès P, Watson H, Kujundzic M, Angeli P, Horsmans Y. Effects of a selective vasopressin V2 receptor antagonist, satavaptan (SR121463B) on recurrence of ascites after large volume paracentesis. Hepatology 2006 44 : 180A.
45. Lenaerts A, Codden T, Henry JP, Legros F, Ligny G. Comparative pilot study of repeated large volume paracentesis vs the combination on clonidine-spironolactone in the treatment of cirrhosis-associated refractory ascites. Gastroenterol. Clin. Biol. 2005 29 : 1137 1142.
46. Lenaerts A, Codden T, Meunier JC, Henry JP, Ligny G. Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system. Hepatology 2006 44 : 844 849.
47. Kalambokis G, Fotopoulos A, Economou M, Pappas K, Tsianos EV. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J. Hepatol. 2007 46 : 213 221.
48. Krag A, Møller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007 46 : 1863 1871.
49. Heuman DM, Abou-Assi SG, Habib A et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004 40 : 802 810.
50. Ginès P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology 2008 48 : 1002 1010.
51. Gerbes AL, Gülberg V, Ginès P et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003 124 : 933 939.
52. Schrier RW, Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 2006 355 : 2099 2112.
53. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007 56 : 1310 1318. (Pubitemid 47300435)
54. Brensing KA, Textor J, Perz J et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000 47 : 288 295.
55. Mitzner SR, Stange J, Klammt S et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl. 2000 6 : 277 286.
56. Sort P, Navasa M, Arroyo V et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N. Engl. J. Med. 1999 341 : 403 409.
57. Rimola A, García-Tsao G, Navasa M et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J. Hepatol. 2000 32 : 142 153.
58. Ageely H, Ayoola EA, al-Hazmi M, Gadour M. Spontaneous bacterial peritonitis in Saudi Arabian patients with non-alcoholic liver cirrhosis. Hepatogastroenterology 2000 47 : 1649 1653.
59. Puri AS, Puri J, Ghoshal UC et al. Frequency, microbial spectrum and outcome of spontaneous bacterial peritonitis in north India. Indian J. Gastroenterol. 1996 15 : 86 9.
60. Koulaouzidis A, Bhat S, Karagiannidis A, Tan WC, Linaker BD. Spontaneous bacterial peritonitis. Postgrad. Med. J. 2007 83 : 379 383.
61. Guarner C, Runyon BA, Young S, Heck M, Sheikh MY. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J. Hepatol. 1997 26 : 1372 1378.
62. Sheer TA, Runyon BA. Spontaneous bacterial peritonitis. Dig. Dis. 2005 23 : 39 46.
63. Lee JH, Yoon JH, Kim BH et al. Enterococcus: not an innocent bystander in cirrhotic patients with spontaneous bacterial peritonitis. Eur. J. Clin. Microbiol. Infect. Dis. 2009 28 : 21 6.
64. Kang CI, Kim SH, Park WB et al. Clinical outcome of bacteremic spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase- producing Escherichia coli and Klebsiella pneumoniae. Taehan Naekwa Hakhoe Chapchi 2004 19 : 160 164.
65. Cheng KC, Chuang YC, Wu LT, Huang GC, Yu WL. Clinical experiences of the infections caused by extended-spectrum beta-lactamase-producing Serratia marcescens at a medical center in Taiwan. Jpn. J. Infect. Dis. 2006 59 : 147 152.
66. Song JY, Jung SJ, Park CW et al. Prognostic significance of infection acquisition sites in spontaneous bacterial peritonitis: nosocomial versus community acquired. J. Korean Med. Sci. 2006 21 : 666 671.
67. Castellote J, López C, Gornals J et al. Rapid diagnosis of spontaneous bacterial peritonitis by use of reagent strips. Hepatology 2003 37 : 893 896.
68. Kim DY, Kim JH, Chon CY et al. Usefulness of urine strip test in the rapid diagnosis of spontaneous bacterial peritonitis. Liver Int. 2005 25 : 1197 1201.
69. Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology 1988 95 : 1351 1355.
70. Amarapurkar DN, Viswanathan N, Parikh SS, Kalro RH, Desai HG. Prevalence of spontaneous bacterial peritonitis. J. Assoc. Physicians India 1992 40 : 236 238.
71. Kim SU, Kim DY, Lee CK et al. Ascitic fluid infection in patients with hepatitis B virus-related liver cirrhosis: culture-negative neutrocytic ascites versus spontaneous bacterial peritonitis. J. Gastroenterol. Hepatol in press).
72. Zapater P, Francés R, González-Navajas JM et al. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology 2008 48 : 1924 1931.
73. Park YH, Lee HC, Song HG et al. Recent increase in antibiotic-resistant microorganisms in patients with spontaneous bacterial peritonitis adversely affects the clinical outcome in Korea. J. Gastroenterol. Hepatol. 2003 18 : 927 933.
74. Cheong HS, Kang CI, Lee JA et al. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin. Infect. Dis. 2009 48 : 1230 1236.
75. Cho JH, Park KH, Kim SH et al. Bacteremia is a prognostic factor for poor outcome in spontaneous bacterial peritonitis. Scand. J. Infect. Dis. 2007 39 : 697 702.
76. Soylu AR, Dokmeci G, Tezel A et al. Predictors of short-term outcome of spontaneous bacterial peritonitis in Turkish cirrhotic patients. J. Gastroenterol. Hepatol. 2005 20 : 657 660.
77. Ghassemi S, Garcia-Tsao G. Prevention and treatment of infections in patients with cirrhosis. Best Pract. Res. Clin. Gastroenterol. 2007 21 : 77 93.
78. Wong F, Bernardi M, Balk R et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut 2005 54 : 718 725.
79. Bernard B, Grangé JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999 29 : 1655 1661.
80. Terg R, Fassio E, Guevara M et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J. Hepatol. 2008 48 : 774 779.
81. Fernández J, Navasa M, Planas R et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007 133 : 818 824.